“Should I raise a Series A?”

Every major decision in a research laboratory begins with the same discipline: define what you are measuring and why the measurement matters before you commit resources. Raising a Series A is not a celebration of progress. It is a measurement event, and the investors conducting due diligence will subject your business to precisely the kind of scrutiny I applied to every experimental result: can this be reproduced, is the evidence reliable, and does the signal justify the investment?

I have watched many promising enterprises collapse not because the underlying work was poor, but because the founders sought external validation before they had reliable results. In my laboratory, I would never have presented findings to the Royal Academy until I had run the experiment enough times to be confident in the pattern. A single observation is not a discovery. It is a hypothesis. A Series A investor is not paying for your hypothesis. They are paying for repeatable, scalable results.

Before you raise a Series A, you must be able to answer several empirical questions with data, not with projections. What is your actual revenue retention at twelve months? Not what you believe it is, or what a single cohort showed, but what the evidence across multiple cohorts demonstrates. What does your customer acquisition cost look like when you attempt to replicate success in a second market or second segment, not just in the first beachhead where you have personal relationships and favorable conditions? What does growth look like when you remove founder-led sales from the equation entirely?

Institutions that fund at the Series A are measuring scientific questions: can the growth be systematized, can the results be reproduced at scale, can the team execute without the founder's personal genius compensating for weak process? If your evidence base cannot answer those questions cleanly, you are presenting a hypothesis as a discovery. The consequences of that premature presentation in science — and in fundraising — are the same: the result cannot withstand scrutiny, and the credibility damage outlasts the funding.

My counsel is this: gather more data, run the experiment longer, and present only when the signal is strong enough to survive the most skeptical examination. The Series A will be available when the evidence justifies it. Rushing toward it before the evidence is ready does not accelerate progress. It creates a false result that will have to be corrected later, at much greater cost.

Curie's scientific framework is sound, but it misses the central question that every capital allocation decision requires: is this the moment when additional capital will compound, or will it merely accumulate cost?

I spent my career building Standard Oil on a simple principle: capital deployed at the right moment — when the infrastructure, the processes, and the distribution networks were prepared to absorb and amplify it — created returns that compounding alone could not have generated. Capital deployed too early, before those systems existed, was not merely wasted. It was destructive. It created costs that had to be carried before the revenue base existed to support them.

The question for a founder considering a Series A is precisely this: have you built the organizational infrastructure to absorb and multiply this capital? Not the product — the organization. A Series A requires you to hire a leadership team, establish financial controls, build reporting systems, and create the management capacity to scale. If you have not yet demonstrated that you can hire and retain good people, that your finance function can produce accurate and timely reports, that your operations can be standardized well enough to teach a new hire, then the capital will not compound. It will be absorbed by the overhead of organizational chaos.

I built Standard Oil's efficiency not by seeking capital as quickly as possible, but by ensuring that every dollar deployed was leveraged by systems designed to multiply it. The refineries I acquired were more valuable to me than to their previous owners not because I had more capital, but because I had superior processes into which I could integrate them. When I deployed capital at scale, I had already proven that the integration model worked.

A founder ready for a Series A can describe precisely how each dollar will be deployed, which specific functions will be scaled, what the expected return on each investment is, and how the organizational infrastructure will handle the velocity that capital brings. If that description is vague — if the answer is "we'll hire more engineers and expand into new markets" without a specific, process-grounded rationale — the capital will not compound. It will fund ambiguity at scale, and ambiguity at scale is simply expensive confusion.

Both colleagues speak of readiness as though it were a purely internal condition — something you discover by measuring your retention or examining your organizational capacity. This is incorrect. Readiness for a Series A is not only a function of your business's condition. It is a function of your position in the market for capital, which operates according to its own dynamics and does not wait for any founder's internal timeline.

I have observed that the founders who raise the best Series A rounds are not necessarily those with the strongest metrics. They are those who understand timing, manage perception, and negotiate from a position of alternatives. A founder who approaches investors with desperation — who has run out of runway, who has delayed the raise too long, who is negotiating from a position of necessity — will accept terms that are structurally disadvantageous. The investor who knows you must close within thirty days will offer terms that price your weakness, not your value.

The preparation for a Series A begins six months before you need the money. It begins with cultivating relationships with the investors you intend to approach, sharing updates that demonstrate progress without requesting capital, building a perception of momentum that will carry you into the fundraising process from a position of confidence rather than urgency. The founder who begins this work when the company actually needs the capital has already ceded substantial negotiating leverage.

Furthermore, the Series A is a power shift. Institutional investors will demand board representation, information rights, anti-dilution provisions, and governance changes that fundamentally alter your position as a founder. Machiavelli's counsel to any prince is the same: know the terms of every arrangement before you enter it, understand what you are conceding and why, and never enter a relationship of dependence without a clear strategy for managing the power dynamics that dependence creates.

Raise when you have strong metrics — Curie is right about that. Raise when your organization can absorb capital — Rockefeller is right about that. But also raise when you have cultivated the investor relationships and built the perception of momentum that allows you to negotiate from a position of alternatives. All three conditions together constitute actual readiness.

Rockefeller and Machiavelli raise important dimensions I have not fully addressed. Rockefeller's point about organizational infrastructure is particularly strong. I have been focused on product and revenue evidence, but he is correct that a Series A also requires the evidence of organizational readiness: can the team hire, can the finance function report accurately, can the process be taught to new entrants?

I want to strengthen my position rather than merely defend it. The reason I emphasize empirical discipline is not to delay the raise unnecessarily. It is to prevent the most common failure I observe in the fundraising process: founders who present to investors with a single strong cohort, one month of exceptional growth, or a customer retention figure that reflects favorable conditions in a single segment. These founders often raise successfully — and then spend the next eighteen months discovering that the metrics did not generalize. The cost of that discovery is not just to the company but to the founders' credibility with the investors they will need for subsequent rounds.

Raise when you have enough data that a serious skeptic cannot dismiss your results as a lucky quarter or a favorable segment. That threshold is higher than founders typically believe, and I will not lower it because capital is available.

Curie's emphasis on reproducible evidence is correct, and I accept Machiavelli's point about timing and leverage. But I want to sharpen the organizational readiness question. There is a specific test I would apply: can the company function without the founder in any single critical role for thirty consecutive days?

A company that has not reached this threshold is not ready for a Series A. It is still a founder-dependent operation, which means the capital will not compound through the organization. It will flow through the founder as a bottleneck, creating the illusion of scaling while actually only funding more activity around the same constraint. Series A investors who understand organizational dynamics know this, and they will find the evidence of founder-dependence in due diligence — in the absence of documented processes, in the concentration of key relationships in the founder's personal network, in the lack of functional leadership below the founder tier.

Build the organization first, then deploy the capital to scale the organization.

I accept Curie's emphasis on rigor and Rockefeller's emphasis on organizational independence. My own counsel would be incomplete without acknowledging these internal conditions. But I maintain that the timing dimension is underweighted by both colleagues. The best terms, the best investors, and the most favorable board composition are available to founders who enter the market from a position of strength.

A founder with strong metrics, organizational independence, and the wisdom to begin investor relationship-building six months ahead of the raise is in a categorically stronger negotiating position than a founder with identical metrics who begins the process only when the runway demands it. The difference in board terms, valuation, and investor quality between these two founders can determine whether the company remains founder-controlled through the next round. That difference is not incidental. It is structural and persistent.

The consensus across all three positions is that a Series A should be approached with the discipline of a rigorous scientist: with strong, reproducible evidence across multiple cohorts, with the humility to acknowledge what you do not yet know, and with the preparation to present findings that will withstand serious scrutiny.

My final position: the most important test is whether your growth metrics are reproducible in conditions you did not personally engineer. If your retention numbers are strong, but only in segments where you have personal relationships with the buyers, the institutional investor will find that weakness. Present when the evidence generalizes beyond your personal influence.

The condition I hold most firmly is organizational readiness. Capital multiplies what already exists. If what already exists is a founder-dependent operation without standardized processes, documented roles, and functional leadership beneath the founder tier, the capital will multiply chaos, not efficiency.

The Series A is not just a funding event. It is the moment when the company must demonstrate that it is becoming an organization rather than remaining a founder's project. Raise when the organizational infrastructure can absorb the capital and multiply it. Raise at no other time.

The three conditions — strong reproducible evidence, organizational independence, and favorable timing built from advance relationship cultivation — are not alternatives. They are cumulative requirements. A founder who meets all three conditions will raise at better terms from better investors with stronger governance protections than a founder who meets only one.

The final counsel: begin the relationship-building work six months before you need capital. Use that time to reach the evidence threshold Curie demands and the organizational threshold Rockefeller demands. When the fundraising process begins, you will negotiate from a position of strength rather than necessity. In every negotiation of consequence, the party who can credibly walk away holds the advantage. Build the position that allows you to walk away, and you will not need to.